EbixCash World Money Becomes the First AD-II Licensed Entity to Receive In-Principle PSP Approval at GIFT IFSC
In-principle authorization granted to Buyforex, a wholly owned subsidiary of EbixCash World…
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy
Approval is supported by data from the DEVOTE study which showed the…
InnoCare Announces Approval of Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China
December 17, 2025 20:48 ET | Source: InnoCare Pharma BEIJING, Dec. 17,…
Clinikk Secures IRDAI Approval, Expands with Three New Health Hubs, and Launches its Diamond OPD Membership
BENGALURU, India, Dec. 17, 2025 /PRNewswire/ -- Healthtech company Clinikk, building India's…
InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial
BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE:…
Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
First FDA approved treatment in 30+ years for more than 2 million…
JASCAYD (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China
The approval marks the first new treatment option for people living with…
Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program
November 28, 2025 20:13 ET | Source: Rakovina Therapeutics Inc VANCOUVER, British…
HKUST Receives Government’s Approval to Establish a New Medical School
Dedicated to Nurturing a New Generation of DoctorsSupporting Hong Kong Become a…
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgANORIGIN Phase…


